{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T01:14:10Z","timestamp":1792199650885,"version":"4.4.0"},"reference-count":159,"publisher":"Springer Science and Business Media LLC","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1007\/s00280-010-1339-4","type":"journal-article","created":{"date-parts":[[2010,5,27]],"date-time":"2010-05-27T06:17:27Z","timestamp":1274941047000},"page":"667-686","source":"Crossref","is-referenced-by-count":60,"title":["Cisplatin-induced emesis: systematic review and meta-analysis of the ferret model and the effects of 5-HT3 receptor antagonists"],"prefix":"10.1007","volume":"67","author":[{"given":"N.","family":"Percie du Sert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. A.","family":"Rudd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. C.","family":"Apfel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P. L. R.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,5,28]]},"reference":[{"key":"1339_CR1","volume-title":"Practical statistics for medical research","author":"DG Altman","year":"1991","unstructured":"Altman DG (1991) Practical statistics for medical research. Chapman & Hall, London"},{"key":"1339_CR2","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.autneu.2006.01.008","volume":"125","author":"PLR Andrews","year":"2006","unstructured":"Andrews PLR, Horn CC (2006) Signals for nausea and emesis: implications for models of upper gastrointestinal diseases. Auton Neurosci 125:100\u2013115","journal-title":"Auton Neurosci"},{"key":"1339_CR3","volume-title":"Handbook of experimental pharmacology","author":"PLR Andrews","year":"2004","unstructured":"Andrews PLR, Rudd JA (2004) The role of tachykinins and the tachykinin NK1 receptor in nausea and emesis. In: Holzer P (ed) Handbook of experimental pharmacology. Springer, Berlin"},{"key":"1339_CR4","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0014-2999(93)90767-C","volume":"232","author":"I Angel","year":"1993","unstructured":"Angel I, Schoemaker H, Prouteau M, Garreau M, Langer SZ (1993) Litoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT3 receptor antagonist and antiemetic properties. Eur J Pharmacol 232:139\u2013145","journal-title":"Eur J Pharmacol"},{"key":"1339_CR5","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/0028-3908(88)90092-5","volume":"27","author":"JM Barnes","year":"1988","unstructured":"Barnes JM, Barnes NM, Costall B, Naylor RJ, Tattersall FD (1988) Reserpine, para-chlorophenylalanine and fenfluramine antagonise cisplatin-induced emesis in the ferret. Neuropharmacology 27:783\u2013790","journal-title":"Neuropharmacology"},{"key":"1339_CR6","first-page":"649P","volume":"92","author":"NM Barnes","year":"1987","unstructured":"Barnes NM, Barry JM, Costall B, Naylor RJ, Tattersall FD (1987) Antagonism by para-chlorophenylalanine of cisplatin-induced emesis. Br J Pharmacol 92:649P","journal-title":"Br J Pharmacol"},{"key":"1339_CR7","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/0028-3908(91)90136-Y","volume":"30","author":"NM Barnes","year":"1991","unstructured":"Barnes NM, Bunce KT, Naylor RJ, Rudd JA (1991) The actions of fentanyl to inhibit drug-induced emesis. Neuropharmacology 30:1073\u20131083","journal-title":"Neuropharmacology"},{"key":"1339_CR8","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1553-2712.2003.tb00056.x","volume":"10","author":"V Bebarta","year":"2003","unstructured":"Bebarta V, Luyten D, Heard K (2003) Emergency medicine animal research: does use of randomization and blinding affect the results? Acad Emerg Med 10:684\u2013687","journal-title":"Acad Emerg Med"},{"key":"1339_CR9","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1038\/bjc.1988.277","volume":"58","author":"J Bermudez","year":"1988","unstructured":"Bermudez J, Boyle EA, Miner WD, Sanger GJ (1988) The anti-emetic potential of the 5-hydroxytryptamine3 receptor antagonist BRL 43694. Br J Cancer 58:644\u2013650","journal-title":"Br J Cancer"},{"key":"1339_CR10","first-page":"131","volume":"3","author":"P Bhandari","year":"1988","unstructured":"Bhandari P, Gupta YK, Seth SD, Chugh A (1988) Emetic profile of cisplatin in dogs. Asia Pac J Pharmacol 3:131\u2013133","journal-title":"Asia Pac J Pharmacol"},{"key":"1339_CR11","first-page":"21","volume":"47","author":"S Bingham","year":"1994","unstructured":"Bingham S, Blower PR, Davey PT, King PD, Sanger GJ, Wardle KA, Nishioka Y (1994) Differences between the anti-emetic efficacies of the 5-HT3 receptor antagonists Granisetron and Azasetron in the conscious ferret. Pharmacometrics 47:21\u201328","journal-title":"Pharmacometrics"},{"issue":"Suppl 1","key":"1339_CR12","first-page":"S8","volume":"26","author":"PR Blower","year":"1990","unstructured":"Blower PR (1990) The role of specific 5-HT3 receptor antagonism in the control of cytostatic drug-induced emesis. Eur J Cancer 26(Suppl 1):S8\u2013S11","journal-title":"Eur J Cancer"},{"key":"1339_CR13","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0960-894X(00)80170-5","volume":"2","author":"E Blum","year":"1992","unstructured":"Blum E, Buchheit KH, Buecher HH, Gamse R, Kloeppner E, Meigel H, Papageorgiou C, Waelchli R, Revesz L (1992) Design and synthesis of novel ligands for the 5-HT4 and the 5-HT4 receptor. Bioorg Med Chem Lett 2:461\u2013466","journal-title":"Bioorg Med Chem Lett"},{"key":"1339_CR14","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0031-6997(25)07328-4","volume":"5","author":"HL Borison","year":"1953","unstructured":"Borison HL, Wang SC (1953) Physiology and pharmacology of vomiting. Pharmacol Rev 5:193\u2013230","journal-title":"Pharmacol Rev"},{"key":"1339_CR15","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1016\/0014-2999(93)90673-6","volume":"249","author":"C Bountra","year":"1993","unstructured":"Bountra C, Bunce K, Dale T, Gardner C, Jordan C, Twissell D, Ward P (1993) Anti-emetic profile of a non-peptide neurokinin NK1 receptor antagonist, CP-99, 994, in ferrets. Eur J Pharmacol 249:R3\u2013R4","journal-title":"Eur J Pharmacol"},{"key":"1339_CR16","doi-asserted-by":"crossref","first-page":"A578","DOI":"10.1016\/S0016-5085(98)82351-2","volume":"114","author":"E Chevalier","year":"1998","unstructured":"Chevalier E, Singh L, Diop L (1998) Anti-emetic effects of PD154075. Gastroenterology 114:A578","journal-title":"Gastroenterology"},{"key":"1339_CR17","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1021\/jm00070a008","volume":"36","author":"RD Clark","year":"1993","unstructured":"Clark RD, Miller AB, Berger J, Repke DB, Weinhardt KK, Kowalczyk BA, Eglen RM, Bonhaus DW, Lee CH, Michel AD et al (1993) 2-(Quinuclidin-3-yl)pyrido[4, 3-b]indol-1-ones and isoquinolin-1-ones. Potent conformationally restricted 5-HT3 receptor antagonists. J Med Chem 36:2645\u20132657","journal-title":"J Med Chem"},{"key":"1339_CR18","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/0028-3908(87)90227-9","volume":"26","author":"B Costall","year":"1987","unstructured":"Costall B, Domeney AM, Gunning SJ, Kelly ME, Naylor RJ, Nohria V, Owera-Atepo JB, Simpson KM, Tan CC, Tattersall D (1987) The action of dazopride to enhance gastric emptying and block emesis. Neuropharmacology 26:669\u2013677","journal-title":"Neuropharmacology"},{"key":"1339_CR19","first-page":"90P","volume":"90","author":"B Costall","year":"1987","unstructured":"Costall B, Domeney AM, Gunning SJ, Naylor RJ, Tattersall D, Tyers MB (1987) GR38032F: a potent and novel inhibitor of cisplatin-induced emesis in the ferret. Br J Pharmacol 90:90P","journal-title":"Br J Pharmacol"},{"key":"1339_CR20","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/0028-3908(90)90167-P","volume":"29","author":"B Costall","year":"1990","unstructured":"Costall B, Domeney AM, Naylor RJ, Owera-Atepo JB, Rudd JA, Tattersall FD (1990) Fluphenazine, ICS 205\u2013930 and dl-fenfluramine differentially antagonise drug-induced emesis in the ferret. Neuropharmacology 29:453\u2013462","journal-title":"Neuropharmacology"},{"key":"1339_CR21","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/0028-3908(86)90030-4","volume":"25","author":"B Costall","year":"1986","unstructured":"Costall B, Domeney AM, Naylor RJ, Tattersall FD (1986) 5-Hydroxytryptamine M-receptor antagonism to prevent cisplatin-induced emesis. Neuropharmacology 25:959\u2013961","journal-title":"Neuropharmacology"},{"key":"1339_CR22","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/0028-3908(87)90094-3","volume":"26","author":"B Costall","year":"1987","unstructured":"Costall B, Domeney AM, Naylor RJ, Tattersall FD (1987) Emesis induced by cisplatin in the ferret as a model for the detection of anti-emetic drugs. Neuropharmacology 26:1321\u20131326","journal-title":"Neuropharmacology"},{"key":"1339_CR23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.2042-7158.1990.tb05361.x","volume":"42","author":"B Costall","year":"1990","unstructured":"Costall B, Naylor RJ, Tattersall FD (1990) The actions of fenfluramine and interaction with 5-HT3 receptor-antagonists to inhibit emesis in the ferret. J Pharm Pharmacol 42:94\u2013101","journal-title":"J Pharm Pharmacol"},{"key":"1339_CR24","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1056\/NEJM199003223221204","volume":"322","author":"LX Cubeddu","year":"1990","unstructured":"Cubeddu LX, Hoffmann IS, Fuenmayor NT, Finn AL (1990) Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 322:810\u2013816","journal-title":"N Engl J Med"},{"key":"1339_CR25","doi-asserted-by":"crossref","first-page":"777","DOI":"10.2165\/00003495-200464070-00013","volume":"64","author":"TM Dando","year":"2004","unstructured":"Dando TM, Perry CM (2004) Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting. Drugs 64:777\u2013794","journal-title":"Drugs"},{"key":"1339_CR26","unstructured":"Davis CJ (1988) Neuropharmacological investigations into the mechanisms of emesis caused by cytotoxic drugs and radiation. Clinical pharmacology. Oxford University, PhD thesis"},{"key":"1339_CR27","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0014-2999(96)00680-2","volume":"316","author":"P Delagrange","year":"1996","unstructured":"Delagrange P, Emerit MB, Merahi N, Abraham C, Morain P, Rault S, Renard P, Pfeiffer B, Guardiola-Lemaitre B, Hamon M (1996) Interaction of S 21007 with 5-HT3 receptors. In vitro and in vivo characterization. Eur J Pharmacol 316:195\u2013203","journal-title":"Eur J Pharmacol"},{"key":"1339_CR28","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.cct.2006.04.004","volume":"28","author":"R DerSimonian","year":"2007","unstructured":"DerSimonian R, Kacker R (2007) Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials 28:105\u2013114","journal-title":"Contemp Clin Trials"},{"key":"1339_CR29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0028-3908(94)90083-3","volume":"33","author":"RM Eglen","year":"1994","unstructured":"Eglen RM, Bonhaus DW, Clark RD, Johnson LG, Lee CH, Leung E, Smith WL, Wong EH, Whiting RL (1994) (R) and (S) RS 56532: mixed 5-HT3 and 5-HT4 receptor ligands with opposing enantiomeric selectivity. Neuropharmacology 33:515\u2013526","journal-title":"Neuropharmacology"},{"key":"1339_CR30","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1111\/j.1476-5381.1995.tb13283.x","volume":"114","author":"RM Eglen","year":"1995","unstructured":"Eglen RM, Lee CH, Smith WL, Johnson LG, Clark R, Whiting RL, Hegde SS (1995) Pharmacological characterization of RS 25259\u2013197, a novel and selective 5-HT3 receptor antagonist, in vivo. Br J Pharmacol 114:860\u2013866","journal-title":"Br J Pharmacol"},{"key":"1339_CR31","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0022-3565(25)38380-1","volume":"266","author":"RM Eglen","year":"1993","unstructured":"Eglen RM, Lee CH, Smith WL, Johnson LG, Whiting RL, Hegde SS (1993) RS 42358\u2013197, a novel and potent 5-HT3 receptor antagonist, in vitro and in vivo. J Pharmacol Exp Ther 266:535\u2013543","journal-title":"J Pharmacol Exp Ther"},{"key":"1339_CR32","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2131\/jts.15.235","volume":"15","author":"T Endo","year":"1990","unstructured":"Endo T, Minami M, Monma Y, Saito H, Takeuchi M (1990) Emesis-related biochemical and histopathological changes induced by cisplatin in the ferret. J Toxicol Sci 15:235\u2013244","journal-title":"J Toxicol Sci"},{"key":"1339_CR33","first-page":"525","volume":"7","author":"T Endo","year":"1990","unstructured":"Endo T, Minami M, Monma Y, Yoshioka M, Saito H, Kinami J, Toshimitsu Y, Parvez SH (1990) Effect of GR38032F on cisplatin- and cyclophosphamide-induced emesis in the ferret. Biog Amines 7:525\u2013533","journal-title":"Biog Amines"},{"key":"1339_CR34","first-page":"163","volume":"9","author":"T Endo","year":"1992","unstructured":"Endo T, Minami M, Monma Y, Yoshioka M, Saito H, Parvez SH (1992) Vagotomy and ondansetron (5-HT3 antagonist) inhibited the increase of serotonin concentration induced by cytotoxic drugs in the area postreama of ferrets. Biog amines 9:163\u2013175","journal-title":"Biog amines"},{"key":"1339_CR35","first-page":"399","volume":"11","author":"T Endo","year":"1995","unstructured":"Endo T, Nemoto M, Minami M, Yoshioka M, Saito H, Parvez SH (1995) Changes in the afferent abdominal vagal nerve activity induced by cisplatin and copper sulfate in the ferret. Biog Amines 11:399\u2013407","journal-title":"Biog Amines"},{"key":"1339_CR36","first-page":"435","volume":"47","author":"T Endo","year":"1994","unstructured":"Endo T, Nemoto M, Monma Y, Hamaue N, Togashi M, Hirafuji M (1994) Combined effect of domperidone and granisetron on cisplatin-induced emesis in the ferret. Pharmacometrics 47:435\u2013442","journal-title":"Pharmacometrics"},{"key":"1339_CR37","unstructured":"European Medicines Agency (2006) Guideline on non-clinical and clinical development of medicinal products for the treatment of nausea and vomiting associated with cancer chemotherapy. CPMP\/EWP\/4937\/03. In: EMEA (ed) London, UK"},{"key":"1339_CR38","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0304-3940(92)90397-P","volume":"137","author":"A Fink-Jensen","year":"1992","unstructured":"Fink-Jensen A, Judge ME, Hansen JB, Jacobsen P, Turski L, Olney J, Honore T (1992) Inhibition of cisplatin-induced emesis in ferrets by the non-NMDA receptor antagonists NBQX and CNQX. Neurosci Lett 137:173\u2013177","journal-title":"Neurosci Lett"},{"key":"1339_CR39","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0022-3565(25)12712-2","volume":"254","author":"LR Fitzpatrick","year":"1990","unstructured":"Fitzpatrick LR, Lambert RM, Pendley CE, Martin GE, Bostwick JS, Gessner GW, Airey JE, Youssefyeh RD, Pendleton RG, Decktor DL (1990) RG 12915: a potent 5-hydroxytryptamine-3 antagonist that is an orally effective inhibitor of cytotoxic drug-induced emesis in the ferret and dog. J Pharmacol Exp Ther 254:450\u2013455","journal-title":"J Pharmacol Exp Ther"},{"key":"1339_CR40","first-page":"187","volume":"66","author":"AP Florczyk","year":"1982","unstructured":"Florczyk AP, Schurig JE, Bradner WT (1982) Cisplatin-induced emesis in the Ferret: a new animal model. Cancer Treat Rep 66:187\u2013189","journal-title":"Cancer Treat Rep"},{"key":"1339_CR41","first-page":"228","volume":"22","author":"AP Florczyk","year":"1981","unstructured":"Florczyk AP, Schurig JE, Lenaz L, Bradner WT (1981) the ferret: a new animal model of cis-platinum induced emesis. Proc Am Assoc Canc Res 22:228","journal-title":"Proc Am Assoc Canc Res"},{"key":"1339_CR42","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0306-3623(98)00102-5","volume":"31","author":"N Fukunaka","year":"1998","unstructured":"Fukunaka N, Sagae S, Kudo R, Endo T, Hirafuji M, Minami M (1998) Effects of granisetron and its combination with dexamethasone on cisplatin-induced delayed emesis in the ferret. Gen Pharmacol 31:775\u2013781","journal-title":"Gen Pharmacol"},{"issue":"Suppl 1","key":"1339_CR43","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1016\/S0959-8049(05)80259-X","volume":"29A","author":"DR Gandara","year":"1993","unstructured":"Gandara, Harvey WH, Monaghan GG, Perez EA, Hesketh PJ (1993) Delayed emesis following high-dose cisplatin: a double-blind randomised comparative trial of ondansetron (GR 38032F) versus placebo. Eur J Cancer 29A(Suppl 1):S35\u2013S38","journal-title":"Eur J Cancer"},{"key":"1339_CR44","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/0167-0115(96)00071-7","volume":"65","author":"CJ Gardner","year":"1996","unstructured":"Gardner CJ, Armour DR, Beattie DT, Gale JD, Hawcock AB, Kilpatrick GJ, Twissell DJ, Ward P (1996) GR205171: a novel antagonist with high affinity for the tachykinin NK1 receptor, and potent broad-spectrum anti-emetic activity. Regul Pept 65:45\u201353","journal-title":"Regul Pept"},{"key":"1339_CR45","first-page":"516P","volume":"112","author":"CJ Gardner","year":"1994","unstructured":"Gardner CJ, Bountra C, Bunce KT, Dale TJ, Jordan CC, Twissell DJ, Ward P (1994) Anti-emetic activity of neurokinin NK1 receptor antagonists is mediated centrally. Br J Pharmacol 112:516P","journal-title":"Br J Pharmacol"},{"key":"1339_CR46","doi-asserted-by":"crossref","first-page":"3158","DOI":"10.1111\/j.1476-5381.1995.tb15118.x","volume":"116","author":"CJ Gardner","year":"1995","unstructured":"Gardner CJ, Twissell DJ, Dale TJ, Gale JD, Jordan CC, Kilpatrick GJ, Bountra C, Ward P (1995) The broad-spectrum anti-emetic activity of the novel non-peptide tachykinin NK1 receptor antagonist GR203040. Br J Pharmacol 116:3158\u20133163","journal-title":"Br J Pharmacol"},{"key":"1339_CR47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/0014-2999(96)00216-6","volume":"305","author":"S Gonsalves","year":"1996","unstructured":"Gonsalves S, Watson J, Ashton C (1996) Broad spectrum antiemetic effects of CP-122, 721, a tachykinin NK1 receptor antagonist, in ferrets. Eur J Pharmacol 305:181\u2013185","journal-title":"Eur J Pharmacol"},{"key":"1339_CR48","doi-asserted-by":"crossref","first-page":"A1147","DOI":"10.1016\/S0016-5085(98)84664-7","volume":"114","author":"CL Gooch","year":"1998","unstructured":"Gooch CL, Boissonade FM, Grundy D (1998) Somatostatin analogue octreotide inhibits retching to cisplatin in anaesthetised ferret. Gastroenterology 114:A1147","journal-title":"Gastroenterology"},{"key":"1339_CR49","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S0022-3565(25)24595-5","volume":"244","author":"JA Gylys","year":"1988","unstructured":"Gylys JA, Wright RN, Nicolosi WD, Buyniski JP, Crenshaw RR (1988) BMY-25801, an antiemetic agent free of D2-dopamine receptor antagonist properties. J Pharmacol Exp Ther 244:830\u2013837","journal-title":"J Pharmacol Exp Ther"},{"key":"1339_CR50","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1254\/jjp.63.377","volume":"63","author":"K Haga","year":"1993","unstructured":"Haga K, Inaba K, Shoji H, Morimoto Y, Fukuda T, Setoguchi M (1993) The effects of orally administered Y-25130, a selective serotonin3-receptor antagonist, on chemotherapeutic agent-induced emesis. Jpn J Pharmacol 63:377\u2013383","journal-title":"Jpn J Pharmacol"},{"key":"1339_CR51","first-page":"285","volume":"28","author":"K Haga","year":"2000","unstructured":"Haga K, Inaba K, Syoji H (2000) The effect of azasetron hydrochloride (serotone (TM)) on delayed emesis induced by a chemotherapeutic agent, cisplatin. Jpn Pharmacol Ther 28:285\u2013290","journal-title":"Jpn Pharmacol Ther"},{"key":"1339_CR52","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1021\/jm990617v","volume":"43","author":"JJ Hale","year":"2000","unstructured":"Hale JJ, Mills SG, MacCoss M, Dorn CP, Finke PE, Budhu RJ, Reamer RA, Huskey SE, Luffer-Atlas D, Dean BJ, McGowan EM, Feeney WP, Chiu SH, Cascieri MA, Chicchi GG, Kurtz MM, Sadowski S, Ber E, Tattersall FD, Rupniak NM, Williams AR, Rycroft W, Hargreaves R, Metzger JM, MacIntyre DE (2000) Phosphorylated morpholine acetal human neurokinin-1 receptor antagonists as water-soluble prodrugs. J Med Chem 43:1234\u20131241","journal-title":"J Med Chem"},{"key":"1339_CR53","doi-asserted-by":"crossref","first-page":"4607","DOI":"10.1021\/jm980299k","volume":"41","author":"JJ Hale","year":"1998","unstructured":"Hale JJ, Mills SG, MacCoss M, Finke PE, Cascieri MA, Sadowski S, Ber E, Chicchi GG, Kurtz M, Metzger J, Eiermann G, Tsou NN, Tattersall FD, Rupniak NM, Williams AR, Rycroft W, Hargreaves R, MacIntyre DE (1998) Structural optimization affording 2-(R)-(1-(R)-3, 5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-1, 2, 4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist. J Med Chem 41:4607\u20134614","journal-title":"J Med Chem"},{"issue":"suppl 2","key":"1339_CR54","first-page":"45","volume":"72","author":"R Hargreaves","year":"1994","unstructured":"Hargreaves R, Tattersall D, Rycroft W, Woodford K, Ladduwahetty T, Keown L, Merchant K, Swain C, MacLeod AM, Baker R, Francis B, Burns D, Cascieri M, Metzger J, MacIntyre DE, Williamson DJ, Iversen LL, Hill RG (1994) Evidence that the anti-emetic effects of NK1 receptor antagonists are centrally mediated. Can J Physiol Pharmacol 72(suppl 2):45","journal-title":"Can J Physiol Pharmacol"},{"key":"1339_CR55","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/978-3-642-70479-6_7","volume-title":"Nausea and vomiting: mechanisms and treatment","author":"AL Harris","year":"1986","unstructured":"Harris AL, Cantwell BMJ (1986) Mechanisms and treatment of cytotoxic-induced nausea and vomiting. In: Davis CJ, Lake-Bakaar GV, Grahame-Smith DG (eds) Nausea and vomiting: mechanisms and treatment. Springer, Berlin, pp 78\u201393"},{"key":"1339_CR56","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1113\/expphysiol.1988.sp003124","volume":"73","author":"J Hawthorn","year":"1988","unstructured":"Hawthorn J, Ostler KJ, Andrews PLR (1988) The role of the abdominal visceral innervation and 5-hydroxytryptamine M-receptors in vomiting induced by the cytotoxic drugs cyclophosphamide and cis-platin in the ferret. Q J Exp Physiol 73:7\u201321","journal-title":"Q J Exp Physiol"},{"key":"1339_CR57","volume-title":"Management of nausea and vomiting in cancer and cancer treatment","author":"PJ Hesketh","year":"2005","unstructured":"Hesketh PJ (2005) Management of nausea and vomiting in cancer and cancer treatment. Jones and Barlett Publishers Inc., Sudbury"},{"key":"1339_CR58","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1200\/JCO.1989.7.6.700","volume":"7","author":"PJ Hesketh","year":"1989","unstructured":"Hesketh PJ, Murphy WK, Lester EP, Gandara DR, Khojasteh A, Tapazoglou E, Sartiano GP, White DR, Werner K, Chubb JM (1989) GR 38032F (GR-C507\/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 7:700\u2013705","journal-title":"J Clin Oncol"},{"key":"1339_CR59","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1476-5381.1989.tb11948.x","volume":"97","author":"GA Higgins","year":"1989","unstructured":"Higgins GA, Kilpatrick GJ, Bunce KT, Jones BJ, Tyers MB (1989) 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol 97:247\u2013255","journal-title":"Br J Pharmacol"},{"key":"1339_CR60","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1016\/j.bmcl.2005.11.111","volume":"16","author":"GJ Hollingworth","year":"2006","unstructured":"Hollingworth GJ, Carlson EJ, Castro JL, Chicchi GG, Clark N, Cooper LC, Dirat O, Salvo JD, Elliott JM, Kilburn R, Kurtz MM, Rycroft W, Tattersall FD, Tsao KL, Swain CJ (2006) Novel lactam NK1 antagonists with anti-emetic activity. Bioorg Med Chem Lett 16:1197\u20131201","journal-title":"Bioorg Med Chem Lett"},{"key":"1339_CR61","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1476-5381.2009.00176.x","volume":"157","author":"AM Holmes","year":"2009","unstructured":"Holmes AM, Rudd JA, Tattersall FD, Aziz Q, Andrews PLR (2009) Opportunities for the replacement of animals in the study of nausea and vomiting. Br J Pharmacol 157:865\u2013880","journal-title":"Br J Pharmacol"},{"key":"1339_CR62","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1161\/hs1001.096009","volume":"32","author":"J Horn","year":"2001","unstructured":"Horn J, de Haan RJ, Vermeulen M, Luiten PG, Limburg M (2001) Nimodipine in animal model experiments of focal cerebral ischemia: a systematic review. Stroke 32:2433\u20132438","journal-title":"Stroke"},{"key":"1339_CR63","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1161\/01.STR.32.2.570","volume":"32","author":"J Horn","year":"2001","unstructured":"Horn J, Limburg M (2001) Calcium antagonists for ischemic stroke: a systematic review. Stroke 32:570\u2013576","journal-title":"Stroke"},{"key":"1339_CR64","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/0014-2999(90)94310-T","volume":"183","author":"T Ito","year":"1990","unstructured":"Ito T, Yoshida N, Miura Y, Omoya H, Karasawa T (1990) Antiemetic effects of AS-5370, a novel serotonin 5-HT3 receptor antagonist. Eur J Pharmacol 183:1214\u20131215","journal-title":"Eur J Pharmacol"},{"key":"1339_CR65","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/S0959-8049(96)00276-6","volume":"33","author":"IT Jantunen","year":"1997","unstructured":"Jantunen IT, Kataja VV, Muhonen TT (1997) An overview of randomised studies comparing 5-HT3 receptor antagonists to conventional anti-emetics in the prophylaxis of acute chemotherapy-induced vomiting. Eur J Cancer 33:66\u201374","journal-title":"Eur J Cancer"},{"key":"1339_CR66","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/0014-2999(93)90868-I","volume":"238","author":"T Kamato","year":"1993","unstructured":"Kamato T, Ito H, Nagakura Y, Nishida A, Yuki H, Yamano M, Miyata K (1993) Mechanisms of cisplatin- and m-chlorophenylbiguanide-induced emesis in ferrets. Eur J Pharmacol 238:369\u2013376","journal-title":"Eur J Pharmacol"},{"key":"1339_CR67","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1254\/jjp.57.387","volume":"57","author":"T Kamato","year":"1991","unstructured":"Kamato T, Miyata K, Ito H, Yuki H, Yamano M, Honda K (1991) Antiemetic effects of YM060, a potent and selective serotonin (5HT)3-receptor antagonist, in ferrets and dogs. Jpn J Pharmacol 57:387\u2013395","journal-title":"Jpn J Pharmacol"},{"key":"1339_CR68","unstructured":"Kilkenny C (2008) Systematic reviews of animal research. Available online at: http:\/\/www.nc3rs.org.uk\/downloaddoc.asp?id=695"},{"key":"1339_CR69","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1007\/BF02969358","volume":"28","author":"JH Kim","year":"2005","unstructured":"Kim JH, Yoon IS, Lee BH, Choi SH, Lee JH, Lee JH, Jeong SM, Kim SC, Park CK, Lee SM, Nah SY (2005) Effects of Korean red ginseng extract on cisplatin-induced nausea and vomiting. Arch Pharm Res 28:680\u2013684","journal-title":"Arch Pharm Res"},{"key":"1339_CR70","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.neulet.2004.11.015","volume":"376","author":"AG King","year":"2005","unstructured":"King AG, Sanger GJ (2005) Effect of a selective and potent central nervous system penetrant, neurokinin-3 receptor antagonist (SB-222200), on cisplatin-induced emesis in the ferret. Neurosci Lett 376:5\u20138","journal-title":"Neurosci Lett"},{"key":"1339_CR71","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/(SICI)1097-0142(19961115)78:10<2193::AID-CNCR22>3.0.CO;2-T","volume":"78","author":"MG Kris","year":"1996","unstructured":"Kris MG, Cubeddu LX, Gralla RJ, Cupissol D, Tyson LB, Venkatraman E, Homesley HD (1996) Are more antiemetic trials with a placebo necessary? Report of patient data from randomized trials of placebo antiemetics with cisplatin. Cancer 78:2193\u20132198","journal-title":"Cancer"},{"key":"1339_CR72","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1200\/JCO.1985.3.10.1379","volume":"3","author":"MG Kris","year":"1985","unstructured":"Kris MG, Gralla RJ, Clark RA, Tyson LB, O\u2019Connell JP, Wertheim MS, Kelsen DP (1985) Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol 3:1379\u20131384","journal-title":"J Clin Oncol"},{"key":"1339_CR73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1248\/yakushi.124.1","volume":"124","author":"Y Kubota","year":"2004","unstructured":"Kubota Y, Mihara K, Ishii F, Ohno K, Ogata H, Makimura M, Kikuchi N, Kitano T (2004) Effectiveness of anti-emetics for the prophylaxis of cisplatin-induced delayed emesis: a systematic review. Yakugaku Zasshi 124:1\u201311","journal-title":"Yakugaku Zasshi"},{"key":"1339_CR74","first-page":"401","volume":"46","author":"B Lasheras","year":"1996","unstructured":"Lasheras B, Berjon A, Montanes R, Roca J, Romero G, Ramirez MJ, Del Rio J (1996) Pharmacological properties of quinoxaline derivatives as a new class of 5-HT3 receptor antagonists. Arzneimittelforschung 46:401\u2013406","journal-title":"Arzneimittelforschung"},{"key":"1339_CR75","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejphar.2004.11.019","volume":"506","author":"AH Lau","year":"2005","unstructured":"Lau AH, Kan KK, Lai HW, Ngan MP, Rudd JA, Wai MK, Yew DT (2005) Action of ondansetron and CP-99, 994 to modify behavior and antagonize cisplatin-induced emesis in the ferret. Eur J Pharmacol 506:241\u2013247","journal-title":"Eur J Pharmacol"},{"key":"1339_CR76","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/0028-3908(96)00008-1","volume":"35","author":"A Lehmann","year":"1996","unstructured":"Lehmann A, Karrberg L (1996) Effects of N-methyl-D-aspartate receptor antagonists on cisplatin-induced emesis in the ferret. Neuropharmacology 35:475\u2013481","journal-title":"Neuropharmacology"},{"key":"1339_CR77","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s00280-005-0179-0","volume":"58","author":"YL Liu","year":"2006","unstructured":"Liu YL, Malik NM, Sanger GJ, Andrews PL (2006) Ghrelin alleviates cancer chemotherapy-associated dyspepsia in rodents. Cancer Chemother Pharmacol 58:326\u2013333","journal-title":"Cancer Chemother Pharmacol"},{"key":"1339_CR78","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/j.1600-079X.2004.00172.x","volume":"38","author":"MR Macleod","year":"2005","unstructured":"Macleod MR, O\u2019Collins T, Horky LL, Howells DW, Donnan GA (2005) Systematic review and meta-analysis of the efficacy of melatonin in experimental stroke. J Pineal Res 38:35\u201341","journal-title":"J Pineal Res"},{"key":"1339_CR79","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/sj.jcbfm.9600064","volume":"25","author":"MR Macleod","year":"2005","unstructured":"Macleod MR, O\u2019Collins T, Horky LL, Howells DW, Donnan GA (2005) Systematic review and metaanalysis of the efficacy of FK506 in experimental stroke. J Cereb Blood Flow Metab 25:713\u2013721","journal-title":"J Cereb Blood Flow Metab"},{"key":"1339_CR80","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/01.STR.0000125719.25853.20","volume":"35","author":"MR Macleod","year":"2004","unstructured":"Macleod MR, O\u2019Collins T, Howells DW, Donnan GA (2004) Pooling of animal experimental data reveals influence of study design and publication bias. Stroke 35:1203\u20131208","journal-title":"Stroke"},{"key":"1339_CR81","first-page":"371P","volume":"104","author":"HE Marr","year":"1992","unstructured":"Marr HE, Davey PT, Blower PR (1992) The effect of dexamethasone, alone or in combination with granisetron, on cisplatin-induced emesis in the ferret. Br J Pharmacol 104:371P","journal-title":"Br J Pharmacol"},{"key":"1339_CR82","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1159\/000139191","volume":"48","author":"HE Marr","year":"1994","unstructured":"Marr HE, Davey PT, Boyle EA, Blower PR (1994) Further studies of the antiemetic activity of granisetron against whole body X-irradiation or cisplatin-induced emesis in the ferret. Pharmacology 48:283\u2013292","journal-title":"Pharmacology"},{"key":"1339_CR83","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/BF01372557","volume":"120","author":"HE Marr","year":"1994","unstructured":"Marr HE, Davey PT, Boyle EA, Blower PR (1994) The antiemetic activity of granisetron against cytostatic-treatment-induced emesis in 10- to 13-week-old ferrets. J Cancer Res Clin Oncol 120:204\u2013207","journal-title":"J Cancer Res Clin Oncol"},{"issue":"Suppl 1","key":"1339_CR84","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000227637","volume":"53","author":"M Martin","year":"1996","unstructured":"Martin M (1996) The severity and pattern of emesis following different cytotoxic agents. Oncology 53(Suppl 1):26\u201331","journal-title":"Oncology"},{"issue":"Suppl 1","key":"1339_CR85","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00001813-199502001-00004","volume":"6","author":"M Marty","year":"1995","unstructured":"Marty M, Kleisbauer JP, Fournel P, Vergnenegre A, Carles P, Loria-Kanza Y, Simonetta C, de Bruijn KM (1995) Is Navoban (tropisetron) as effective as Zofran (ondansetron) in cisplatin-induced emesis? The French Navoban Study Group. Anticancer Drugs 6(Suppl 1):15\u201321","journal-title":"Anticancer Drugs"},{"key":"1339_CR86","doi-asserted-by":"crossref","first-page":"3307","DOI":"10.1021\/jm00096a001","volume":"35","author":"T Matsui","year":"1992","unstructured":"Matsui T, Sugiura T, Nakai H, Iguchi S, Shigeoka S, Takada H, Odagaki Y, Nagao Y, Ushio Y, Ohmoto K et al (1992) Novel 5-HT3 antagonists. Isoquinolinones and 3-aryl-2-pyridones. J Med Chem 35:3307\u20133319","journal-title":"J Med Chem"},{"key":"1339_CR87","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/bmj.313.7061.862","volume":"313","author":"JN Matthews","year":"1996","unstructured":"Matthews JN, Altman DG (1996) Interaction 3: How to examine heterogeneity. BMJ 313:862","journal-title":"BMJ"},{"key":"1339_CR88","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1258\/jrsm.2007.070164","volume":"101","author":"RA Matthews","year":"2008","unstructured":"Matthews RA (2008) Medical progress depends on animal models\u2014doesn\u2019t it? J R Soc Med 101:95\u201398","journal-title":"J R Soc Med"},{"key":"1339_CR89","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1152\/ajplegacy.1974.226.3.738","volume":"226","author":"LE McCarthy","year":"1974","unstructured":"McCarthy LE, Borison HL (1974) Respiratory mechanics of vomiting in decerebrate cats. Am J Physiol 226:738\u2013743","journal-title":"Am J Physiol"},{"key":"1339_CR90","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/ddr.430280111","volume":"28","author":"RC Miller","year":"1993","unstructured":"Miller RC, Galvan M, Gittos MW, Van Giersbergen PLM, Moser PC, Fozard JR (1993) Pharmacological properties of dolasetron, a potent and selective antagonist at 5-HT3 receptors. Drug Dev Res 28:87\u201393","journal-title":"Drug Dev Res"},{"key":"1339_CR91","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0014-2999(98)00784-5","volume":"363","author":"M Minami","year":"1998","unstructured":"Minami M, Endo T, Kikuchi K, Ihira E, Hirafuji M, Hamaue N, Monma Y, Sakurada T, Tan-no K, Kisara K (1998) Antiemetic effects of sendide, a peptide tachykinin NK1 receptor antagonist, in the ferret. Eur J Pharmacol 363:49\u201355","journal-title":"Eur J Pharmacol"},{"issue":"suppl 2","key":"1339_CR92","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2131\/jts.16.SupplementII_35","volume":"16","author":"M Minami","year":"1991","unstructured":"Minami M, Endo T, Monma Y, Shiroshita Y (1991) Pharmacoogy of emesis induced by anti cancer drugs. J Toxicol Sci 16(suppl 2):35\u201339","journal-title":"J Toxicol Sci"},{"key":"1339_CR93","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0014-2999(96)00974-0","volume":"321","author":"M Minami","year":"1997","unstructured":"Minami M, Endo T, Tamakai H, Ogawa T, Hamaue N, Hirafuji M, Monma Y, Yoshioka M, Hagihara K (1997) Antiemetic effects of N-3389, a newly synthesized 5-HT3 and 5-HT4 receptor antagonist, in ferrets. Eur J Pharmacol 321:333\u2013342","journal-title":"Eur J Pharmacol"},{"key":"1339_CR94","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/j.1476-5381.1986.tb10228.x","volume":"88","author":"WD Miner","year":"1986","unstructured":"Miner WD, Sanger GJ (1986) Inhibition of cisplatin-induced vomiting by selective 5-hydroxytryptamine M-receptor antagonism. Br J Pharmacol 88:497\u2013499","journal-title":"Br J Pharmacol"},{"key":"1339_CR95","doi-asserted-by":"crossref","first-page":"374P","DOI":"10.1111\/j.1476-5381.1986.tb10228.x","volume":"88","author":"WD Miner","year":"1986","unstructured":"Miner WD, Sanger GJ, Turner DH (1986) Comparison of the effect of BRL 24924, metoclopramide and domperidone on cisplatin-induced emesis in the ferret. Br J Pharmacol 88:374P","journal-title":"Br J Pharmacol"},{"key":"1339_CR96","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/bjc.1987.177","volume":"56","author":"WD Miner","year":"1987","unstructured":"Miner WD, Sanger GJ, Turner DH (1987) Evidence that 5-hydroxytryptamine3 receptors mediate cytotoxic drug and radiation-evoked emesis. Br J Cancer 56:159\u2013162","journal-title":"Br J Cancer"},{"key":"1339_CR97","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1016\/S0140-6736(99)04149-5","volume":"354","author":"D Moher","year":"1999","unstructured":"Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF (1999) Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of reporting of meta-analyses. Lancet 354:1896\u20131900","journal-title":"Lancet"},{"key":"1339_CR98","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1021\/jm00403a011","volume":"31","author":"I Monkovic","year":"1988","unstructured":"Monkovic I, Willner D, Adam MA, Brown M, Crenshaw RR, Fuller CE, Juby PF, Luke GM, Matiskella JA, Montzka TA (1988) Substituted benzamides. 1. Potential nondopaminergic antagonists of chemotherapy-induced nausea and emesis. J Med Chem 31:1548\u20131558","journal-title":"J Med Chem"},{"key":"1339_CR99","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1254\/jphs.FPJ05001X","volume":"98","author":"H Nakayama","year":"2005","unstructured":"Nakayama H, Yamakuni H, Higaki M, Ishikawa H, Imazumi K, Matsuo M, Mutoh S (2005) Antiemetic activity of FK1052, a 5-HT3- and 5-HT4-receptor antagonist, in Suncus murinus and ferrets. J Pharmacol Sci 98:396\u2013403","journal-title":"J Pharmacol Sci"},{"key":"1339_CR100","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1200\/JCO.1995.13.9.2408","volume":"13","author":"RM Navari","year":"1995","unstructured":"Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, Beck TM, Chang AY, Greenberg B, Caldwell KC et al (1995) Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo. J Clin Oncol 13:2408\u20132416","journal-title":"J Clin Oncol"},{"key":"1339_CR101","unstructured":"Nuffield Council on Bioethics (2005) The ethics of research involving animals. In: Bioethics NCo (ed) London"},{"key":"1339_CR102","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1248\/cpb.44.1707","volume":"44","author":"M Ohta","year":"1996","unstructured":"Ohta M, Suzuki T, Furuya T, Kurihara H, Tokunaga T, Miyata K, Yanagisawa I (1996) Novel 5-hydroxytryptamine (5-HT3) receptor antagonists. III. Pharmacological evaluations and molecular modeling studies of optically active 4,5,6,7-tetrahydro-1H-benzimidazole derivatives. Chem Pharm Bull (Tokyo) 44:1707\u20131716","journal-title":"Chem Pharm Bull (Tokyo)"},{"key":"1339_CR103","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0306-3623(98)00286-9","volume":"33","author":"A Ozaki","year":"1999","unstructured":"Ozaki A, Sukamoto T (1999) Improvement of cisplatin-induced emesis and delayed gastric emptying by KB-R6933, a novel 5-HT3 receptor antagonist. Gen Pharmacol 33:283\u2013288","journal-title":"Gen Pharmacol"},{"key":"1339_CR104","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neulet.2009.08.075","volume":"465","author":"N Percie du Sert","year":"2009","unstructured":"Percie du Sert N, Rudd JA, Moss R, Andrews PLR (2009) The delayed phase of cisplatin-induced emesis is mediated by the area postrema and not the abdominal visceral innervation in the ferret. Neurosci Lett 465:16\u201320","journal-title":"Neurosci Lett"},{"key":"1339_CR105","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1136\/bmj.328.7438.514","volume":"328","author":"P Pound","year":"2004","unstructured":"Pound P, Ebrahim S, Sandercock P, Bracken MB, Roberts I (2004) Where is the evidence that animal research benefits humans? BMJ 328:514\u2013517","journal-title":"BMJ"},{"key":"1339_CR106","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0014-2999(92)90721-F","volume":"221","author":"P Preziosi","year":"1992","unstructured":"Preziosi P, D\u2019Amato M, Del Carmine R, Martire M, Pozzoli G, Navarra P (1992) The effects of 5-HT3 receptor antagonists on cisplatin-induced emesis in the pigeon. Eur J Pharmacol 221:343\u2013350","journal-title":"Eur J Pharmacol"},{"key":"1339_CR107","first-page":"377","volume":"16","author":"MT Price","year":"1990","unstructured":"Price MT, Olney JE (1990) Excitatory amino acid antagonists as anti-emetics. Soc Neurosci Abstr 16:377","journal-title":"Soc Neurosci Abstr"},{"key":"1339_CR108","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/0006-8993(91)91654-J","volume":"565","author":"DJ Reynolds","year":"1991","unstructured":"Reynolds DJ, Barber NA, Grahame-Smith DG, Leslie RA (1991) Cisplatin-evoked induction of c-fos protein in the brainstem of the ferret: the effect of cervical vagotomy and the anti-emetic 5-HT3 receptor antagonist granisetron (BRL 43694). Brain Res 565:231\u2013236","journal-title":"Brain Res"},{"key":"1339_CR109","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1093\/annonc\/mdj944","volume":"17","author":"F Roila","year":"2006","unstructured":"Roila F, Hesketh PJ, Herrstedt J (2006) Prevention of chemotherapy- and radiotherapy-induced emesis: results of the 2004 Perugia International Antiemetic Consensus Conference. Ann Oncol 17:20\u201328","journal-title":"Ann Oncol"},{"key":"1339_CR110","first-page":"15","volume-title":"Management of Nausea and vomiting in cancer and cancer treatment","author":"JA Rudd","year":"2005","unstructured":"Rudd JA, Andrews PLR (2005) Mechanisms of acute and delayed Nausea and vomiting induced by anticancer therapies. In: Hesketh P (ed) Management of Nausea and vomiting in cancer and cancer treatment. Jones and Barlett Publishers, Inc., Sudbury, pp 15\u201366"},{"key":"1339_CR111","doi-asserted-by":"crossref","first-page":"101P","DOI":"10.1111\/j.1476-5381.1992.tb14300.x","volume":"106","author":"JA Rudd","year":"1992","unstructured":"Rudd JA, Bunce KT, Naylor RJ (1992) The effect of 8-OH-DPAT on drug-induced emesis in the ferret. Br J Pharmacol 106:101P","journal-title":"Br J Pharmacol"},{"key":"1339_CR112","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0028-3908(95)00137-9","volume":"35","author":"JA Rudd","year":"1996","unstructured":"Rudd JA, Bunce KT, Naylor RJ (1996) The interaction of dexamethasone with ondansetron on drug-induced emesis in the ferret. Neuropharmacology 35:91\u201397","journal-title":"Neuropharmacology"},{"key":"1339_CR113","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1254\/jjp.78.253","volume":"78","author":"JA Rudd","year":"1998","unstructured":"Rudd JA, Cheng CH, Naylor RJ (1998) Serotonin-independent model of cisplatin-induced emesis in the ferret. Jpn J Pharmacol 78:253\u2013260","journal-title":"Jpn J Pharmacol"},{"key":"1339_CR114","doi-asserted-by":"crossref","first-page":"R1","DOI":"10.1016\/0014-2999(94)90048-5","volume":"262","author":"JA Rudd","year":"1994","unstructured":"Rudd JA, Jordan CC, Naylor RJ (1994) Profiles of emetic action of cisplatin in the ferret: a potential model of acute and delayed emesis. Eur J Pharmacol 262:R1\u2013R2","journal-title":"Eur J Pharmacol"},{"key":"1339_CR115","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1476-5381.1996.tb15761.x","volume":"119","author":"JA Rudd","year":"1996","unstructured":"Rudd JA, Jordan CC, Naylor RJ (1996) The action of the NK1 tachykinin receptor antagonist, CP 99, 994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br J Pharmacol 119:931\u2013936","journal-title":"Br J Pharmacol"},{"key":"1339_CR116","unstructured":"Rudd JA, Kan KW, Ngan MP, Okuno T, Sam TS (2001) Anti-emetic action of intranasally administered metoclopramide in the ferret. Presented at: 7th Hong Kong Pharmacology Society Scientific meeting in Association with the Zhjiang Pharmacological Society, Hong Kong, China, 16\u201318 October"},{"key":"1339_CR117","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1016\/0028-3908(94)90136-8","volume":"33","author":"JA Rudd","year":"1994","unstructured":"Rudd JA, Naylor RJ (1994) Effects of 5-HT3 receptor antagonists on models of acute and delayed emesis induced by cisplatin in the ferret. Neuropharmacology 33:1607\u20131608","journal-title":"Neuropharmacology"},{"key":"1339_CR118","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/0928-4680(94)90009-4","volume":"1","author":"JA Rudd","year":"1994","unstructured":"Rudd JA, Naylor RJ (1994) Modulation of emesis by 5HT1A receptors. Pathophysiology 1:267\u2013268","journal-title":"Pathophysiology"},{"key":"1339_CR119","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1476-5381.1996.tb15388.x","volume":"118","author":"JA Rudd","year":"1996","unstructured":"Rudd JA, Naylor RJ (1996) An interaction of ondansetron and dexamethasone antagonizing cisplatin-induced acute and delayed emesis in the ferret. Br J Pharmacol 118:209\u2013214","journal-title":"Br J Pharmacol"},{"key":"1339_CR120","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0014-2999(97)00073-3","volume":"322","author":"JA Rudd","year":"1997","unstructured":"Rudd JA, Naylor RJ (1997) The actions of ondansetron and dexamethasone to antagonise cisplatin-induced emesis in the ferret. Eur J Pharmacol 322:79\u201382","journal-title":"Eur J Pharmacol"},{"key":"1339_CR121","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0014-2999(98)00359-8","volume":"352","author":"JA Rudd","year":"1998","unstructured":"Rudd JA, Ngan MP, Wai MK (1998) 5-HT3 receptors are not involved in conditioned taste aversions induced by 5-hydroxytryptamine, ipecacuanha or cisplatin. Eur J Pharmacol 352:143\u2013149","journal-title":"Eur J Pharmacol"},{"key":"1339_CR122","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neulet.2005.08.062","volume":"392","author":"JA Rudd","year":"2006","unstructured":"Rudd JA, Ngan MP, Wai MK, King AG, Witherington J, Andrews PLR, Sanger GJ (2006) Anti-emetic activity of ghrelin in ferrets exposed to the cytotoxic anti-cancer agent cisplatin. Neurosci Lett 392:79\u201383","journal-title":"Neurosci Lett"},{"key":"1339_CR123","volume-title":"A COX and LOX inhibitor regimen fails to mimic the action of dexamethasone on cisplatin-induced acute and delayed emesis in the Ferret","author":"JA Rudd","year":"2006","unstructured":"Rudd JA, Sam TS, Ngan MP (2006) A COX and LOX inhibitor regimen fails to mimic the action of dexamethasone on cisplatin-induced acute and delayed emesis in the Ferret. IUPHAR-2006, Beijing"},{"key":"1339_CR124","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000227321","volume":"51","author":"P Ruff","year":"1994","unstructured":"Ruff P, Paska W, Goedhals L, Pouillart P, Riviere A, Vorobiof D, Bloch B, Jones A, Martin C, Brunet R et al (1994) Ondansetron compared with granisetron in the prophylaxis of cisplatin-induced acute emesis: a multicentre double-blind, randomised, parallel-group study. The Ondansetron and Granisetron Emesis Study Group. Oncology 51:113\u2013118","journal-title":"Oncology"},{"key":"1339_CR125","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0014-2999(97)85415-5","volume":"326","author":"NM Rupniak","year":"1997","unstructured":"Rupniak NM, Tattersall FD, Williams AR, Rycroft W, Carlson EJ, Cascieri MA, Sadowski S, Ber E, Hale JJ, Mills SG, MacCoss M, Seward E, Huscroft I, Owen S, Swain CJ, Hill RG, Hargreaves RJ (1997) In vitro and in vivo predictors of the anti-emetic activity of tachykinin NK1 receptor antagonists. Eur J Pharmacol 326:201\u2013209","journal-title":"Eur J Pharmacol"},{"key":"1339_CR126","unstructured":"Russell WM, Burch RL (1959) The principles of humane experimental technique. Universities Federation For Animal Welfare (UFAW)"},{"key":"1339_CR127","unstructured":"Rycroft W, Tattersall D, Ber E, Cascieri M, Hale JJ, Hill RG, MacCoss M, Mills SG, Sadowski S, Hargreaves R (1996) The anti-emetic actions of L-742,694, poster"},{"key":"1339_CR128","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0014-2999(01)00915-3","volume":"417","author":"TS Sam","year":"2001","unstructured":"Sam TS, Chan SW, Rudd JA, Yeung JH (2001) Action of glucocorticoids to antagonise cisplatin-induced acute and delayed emesis in the ferret. Eur J Pharmacol 417:231\u2013237","journal-title":"Eur J Pharmacol"},{"key":"1339_CR129","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0014-2999(03)01550-4","volume":"466","author":"TS Sam","year":"2003","unstructured":"Sam TS, Kan KK, Ngan MP, Rudd JA, Yeung JH (2003) Action of metyrapone and tetracosactrin to modify cisplatin-induced acute and delayed emesis in the ferret. Eur J Pharmacol 466:163\u2013168","journal-title":"Eur J Pharmacol"},{"key":"1339_CR130","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1254\/jphs.FP0061169","volume":"103","author":"TS Sam","year":"2007","unstructured":"Sam TS, Ngan MP, Riendeau D, Robichaud A, Rudd JA (2007) Action of cyclooxygenase inhibitors and a leukotriene biosynthesis inhibitor on cisplatin-induced acute and delayed emesis in the ferret. J Pharmacol Sci 103:189\u2013200","journal-title":"J Pharmacol Sci"},{"key":"1339_CR131","first-page":"1831","volume":"66","author":"JE Schurig","year":"1982","unstructured":"Schurig JE, Florczyk AP, Rose WC, Bradner WT (1982) Antiemetic activity of butorphanol against cisplatin-induced emesis in ferrets and dogs. Cancer Treat Rep 66:1831\u20131835","journal-title":"Cancer Treat Rep"},{"key":"1339_CR132","doi-asserted-by":"crossref","first-page":"31","DOI":"10.2131\/jts.18.31","volume":"18","author":"Y Shiroshita","year":"1993","unstructured":"Shiroshita Y, Minami M, Endo T, Monma Y, Asaka M, Itoh H, Ikeda T, Matsumoto H, Satoh T (1993) The protective effect of 4-hydroxy-2-methyl-N-[2-(tetrazol-5-yl)- phenyl]-2H\u20131, 2-benzothiazine-3-carboxamide-1, 1-dioxide monosodium salt (HX-1920) on cisplatin-induced toxicity in rats. J Toxicol Sci 18:31\u201341","journal-title":"J Toxicol Sci"},{"key":"1339_CR133","doi-asserted-by":"crossref","first-page":"419P","DOI":"10.1016\/S0021-5198(19)49750-3","volume":"58","author":"Y Shiroshita","year":"1992","unstructured":"Shiroshita Y, Minami M, Endo T, Takahashi M, Monma Y, Hiromishi I, Yokoyama R, Matsumoto K (1992) Effects of HX-1920 on cisplatin-induced toxicity in mice, rat and ferrets. Jpn J Pharmacol 58:419P","journal-title":"Jpn J Pharmacol"},{"key":"1339_CR134","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0014-2999(96)00950-8","volume":"321","author":"L Singh","year":"1997","unstructured":"Singh L, Field MJ, Hughes J, Kuo BS, Suman-Chauhan N, Tuladhar BR, Wright DS, Naylor RJ (1997) The tachykinin NK1 receptor antagonist PD 154075 blocks cisplatin-induced delayed emesis in the ferret. Eur J Pharmacol 321:209\u2013216","journal-title":"Eur J Pharmacol"},{"key":"1339_CR135","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/1568010043343822","volume":"3","author":"D Spina","year":"2004","unstructured":"Spina D (2004) The potential of PDE4 inhibitors in respiratory disease. Curr Drug Targets Inflamm Allergy 3:231\u2013236","journal-title":"Curr Drug Targets Inflamm Allergy"},{"key":"1339_CR136","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0305-7372(87)90026-0","volume":"14","author":"R Stables","year":"1987","unstructured":"Stables R, Andrews PLR, Bailey HE, Costall B, Gunning SJ, Hawthorn J, Naylor RJ, Tyers MB (1987) Antiemetic properties of the 5HT3-receptor antagonist, GR38032F. Cancer Treat Rev 14:333\u2013336","journal-title":"Cancer Treat Rev"},{"key":"1339_CR137","first-page":"799","volume":"32","author":"S Taniguchi","year":"2004","unstructured":"Taniguchi S, Hagihara K, Hamada T, Minami M, Endo T, Tsuchiyama M (2004) The inhibitory action of indisetron hydrochloride, a 5-HT3 receptor antagonist, against the anticancer drug-induced emesis in the dog, ferret and suncus. Jpn Pharmacol Ther 32:799\u2013806","journal-title":"Jpn Pharmacol Ther"},{"key":"1339_CR138","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1016\/0014-2999(90)92317-C","volume":"183","author":"D Tattersall","year":"1990","unstructured":"Tattersall FD, Dourish CT, Duchnowski M, Swain C, Iversen SD (1990) The anti-emetic action of the novel 5-HT3 receptor antagonist L-683, 877 in the ferret. Eur J Pharmacol 183:1966\u20131967","journal-title":"Eur J Pharmacol"},{"key":"1339_CR139","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ddr.430250103","volume":"25","author":"D Tattersall","year":"1992","unstructured":"Tattersall D, Newberry N, Beer MS, Rigby M, Gilbert M, Maguire JJ, Mudukotuwa N, Duchnowski M, MacKnight AT, Swain C, Kneen C, Dourish CT (1992) L-683, 877: Pharmacological Profile of a Novel 5-HT3 Receptor Antagonist. Drug Dev Res 25:17\u201328","journal-title":"Drug Dev Res"},{"key":"1339_CR140","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1016\/S0028-3908(99)00172-0","volume":"39","author":"FD Tattersall","year":"2000","unstructured":"Tattersall FD, Rycroft W, Cumberbatch M, Mason G, Tye S, Williamson DJ, Hale JJ, Mills SG, Finke PE, MacCoss M, Sadowski S, Ber E, Cascieri M, Hill RG, MacIntyre DE, Hargreaves RJ (2000) The novel NK1 receptor antagonist MK-0869 (L-754, 030) and its water soluble phosphoryl prodrug, L-758, 298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology 39:652\u2013663","journal-title":"Neuropharmacology"},{"key":"1339_CR141","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/S0028-3908(96)00020-2","volume":"35","author":"FD Tattersall","year":"1996","unstructured":"Tattersall FD, Rycroft W, Francis B, Pearce D, Merchant K, MacLeod AM, Ladduwahetty T, Keown L, Swain C, Baker R, Cascieri M, Ber E, Metzger J, MacIntyre DE, Hill RG, Hargreaves RJ (1996) Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology 35:1121\u20131129","journal-title":"Neuropharmacology"},{"key":"1339_CR142","doi-asserted-by":"crossref","first-page":"R5","DOI":"10.1016\/0014-2999(93)90649-3","volume":"250","author":"FD Tattersall","year":"1993","unstructured":"Tattersall FD, Rycroft W, Hargreaves RJ, Hill RG (1993) The tachykinin NK1 receptor antagonist CP-99, 994 attenuates cisplatin induced emesis in the ferret. Eur J Pharmacol 250:R5\u2013R6","journal-title":"Eur J Pharmacol"},{"key":"1339_CR143","unstructured":"The Cochrane Collaboration\u00ae (2002) Open Learning Material"},{"key":"1339_CR144","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000063796","volume":"66","author":"M Tsuchiya","year":"2002","unstructured":"Tsuchiya M, Fujiwara Y, Kanai Y, Mizutani M, Shimada K, Suga O, Ueda S, Watson JW, Nagahisa A (2002) Anti-emetic activity of the novel nonpeptide tachykinin NK1 receptor antagonist ezlopitant (CJ-11, 974) against acute and delayed cisplatin-induced emesis in the ferret. Pharmacology 66:144\u2013152","journal-title":"Pharmacology"},{"key":"1339_CR145","doi-asserted-by":"crossref","unstructured":"Twissell DJ, Bountra C, Bunce KT, Dale TJ, Gardner CJ, Jordan CC, Ward P (1993) Anti-emetic properties of a non-peptide neurokinin NK1 antagonist, CP-99,994, in ferrets","DOI":"10.1016\/0014-2999(93)90673-6"},{"key":"1339_CR146","doi-asserted-by":"crossref","first-page":"G566","DOI":"10.1152\/ajpgi.00113.2003","volume":"285","author":"MD Sickle Van","year":"2003","unstructured":"Van Sickle MD, Oland LD, Mackie K, Davison JS, Sharkey KA (2003) Delta9-tetrahydrocannabinol selectively acts on CB1 receptors in specific regions of dorsal vagal complex to inhibit emesis in ferrets. Am J Physiol Gastrointest Liver Physiol 285:G566\u2013G576","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"1339_CR147","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1254\/jphs.08027FP","volume":"107","author":"Y Watanabe","year":"2008","unstructured":"Watanabe Y, Okamoto M, Ishii T, Takatsuka S, Taniguchi H, Nagasaki M, Saito A (2008) Long-lasting anti-emetic effect of T-2328, a novel NK(1) antagonist. J Pharmacol Sci 107:151\u2013158","journal-title":"J Pharmacol Sci"},{"key":"1339_CR148","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1111\/j.1476-5381.1995.tb16324.x","volume":"115","author":"JW Watson","year":"1995","unstructured":"Watson JW, Gonsalves SF, Fossa AA, McLean S, Seeger T, Obach S, Andrews PLR (1995) The anti-emetic effects of CP-99, 994 in the ferret and the dog: role of the NK1 receptor. Br J Pharmacol 115:84\u201394","journal-title":"Br J Pharmacol"},{"key":"1339_CR149","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1254\/jphs.SCJ05007X","volume":"101","author":"H Yamakuni","year":"2006","unstructured":"Yamakuni H, Nakayama H, Matsui S, Imazumi K, Matsuo M, Mutoh S (2006) Inhibitory effect of zacopride on Cisplatin-induced delayed emesis in ferrets. J Pharmacol Sci 101:99\u2013102","journal-title":"J Pharmacol Sci"},{"key":"1339_CR150","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0014-2999(02)01541-8","volume":"442","author":"H Yamakuni","year":"2002","unstructured":"Yamakuni H, Sawai-Nakayama H, Imazumi K, Maeda Y, Matsuo M, Manda T, Mutoh S (2002) Resiniferatoxin antagonizes cisplatin-induced emesis in dogs and ferrets. Eur J Pharmacol 442:273\u2013278","journal-title":"Eur J Pharmacol"},{"key":"1339_CR151","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1016\/S0022-3565(25)11423-7","volume":"260","author":"N Yoshida","year":"1992","unstructured":"Yoshida N, Omoya H, Ito T (1992) DAT-582, a novel serotonin3 receptor antagonist, is a potent and long-lasting antiemetic agent in the ferret and dog. J Pharmacol Exp Ther 260:1159\u20131165","journal-title":"J Pharmacol Exp Ther"},{"key":"1339_CR152","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0014-2999(92)90442-7","volume":"216","author":"N Yoshida","year":"1992","unstructured":"Yoshida N, Omoya H, Kato S, Ito T (1992) 5-HT3 receptor antagonist effects of DAT-582, (R) enantiomer of AS-5370. Eur J Pharmacol 216:435\u2013440","journal-title":"Eur J Pharmacol"},{"key":"1339_CR153","first-page":"1078","volume":"43","author":"N Yoshida","year":"1993","unstructured":"Yoshida N, Omoya H, Kato S, Ito T (1993) Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals. Arzneimittelforschung 43:1078\u20131083","journal-title":"Arzneimittelforschung"},{"issue":"sup 1","key":"1339_CR154","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0021-5198(19)39543-5","volume":"55","author":"N Yoshida","year":"1991","unstructured":"Yoshida N, Omoya H, Une T, Ito T, kato S (1991) Pharmacological profile of the stereoisomers of AS-5370, a novel 5HT3 receptor antagonist. Jpn J Pharmacol 55(sup 1):385","journal-title":"Jpn J Pharmacol"},{"key":"1339_CR155","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/0014-2999(96)00061-1","volume":"301","author":"T Yoshikawa","year":"1996","unstructured":"Yoshikawa T, Yoshida N, Hosoki K (1996) Involvement of dopamine D3 receptors in the area postrema in R(+)-7-OH-DPAT-induced emesis in the ferret. Eur J Pharmacol 301:143\u2013149","journal-title":"Eur J Pharmacol"},{"key":"1339_CR156","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0014-2999(01)01459-5","volume":"431","author":"T Yoshikawa","year":"2001","unstructured":"Yoshikawa T, Yoshida N, Oka M (2001) Central antiemetic effects of AS-8112, a dopamine D2, D3, and 5-HT(3) receptor antagonist, in ferrets. Eur J Pharmacol 431:361\u2013364","journal-title":"Eur J Pharmacol"},{"key":"1339_CR157","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/sj.bjp.0704078","volume":"133","author":"T Yoshikawa","year":"2001","unstructured":"Yoshikawa T, Yoshida N, Oka M (2001) The broad-spectrum anti-emetic activity of AS-8112, a novel dopamine D2, D3 and 5-HT3 receptors antagonist. Br J Pharmacol 133:253\u2013260","journal-title":"Br J Pharmacol"},{"key":"1339_CR158","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1021\/jm00083a015","volume":"35","author":"RD Youssefyeh","year":"1992","unstructured":"Youssefyeh RD, Campbell HF, Airey JE, Klein S, Schnapper M, Powers M, Woodward R, Rodriguez W, Golec S, Studt W et al (1992) Development of high-affinity 5-HT3 receptor antagonists. 2. Two novel tricyclic benzamides. J Med Chem 35:903\u2013911","journal-title":"J Med Chem"},{"key":"1339_CR159","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1021\/jm00083a014","volume":"35","author":"RD Youssefyeh","year":"1992","unstructured":"Youssefyeh RD, Campbell HF, Klein S, Airey JE, Darkes P, Powers M, Schnapper M, Neuenschwander K, Fitzpatrick LR, Pendley CE et al (1992) Development of high-affinity 5-HT3 receptor antagonists. 1. Initial structure-activity relationship of novel benzamides. J Med Chem 35:895\u2013903","journal-title":"J Med Chem"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s00280-010-1339-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:00:55Z","timestamp":1740121255000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-010-1339-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,5,28]]},"references-count":159,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["1339"],"URL":"https:\/\/doi.org\/10.1007\/s00280-010-1339-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,5,28]]}}}